stockrow
Saturday 7 November 2026
Export LBRX’s income statement to Excel — free account
LB Pharmaceuticals Inc
LBRX Healthcare Biotechnology
- EPS
- +87.4%
- Free cash flow
- −579.0%
Quarter to June 2026, against a year earlier
42.01
3.92
+10.29%
Follow LBRX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 2 | 2 | 2 | 0.0% | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | — | — | (63) | (25) | (86) | (60.1%) | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | — | — | — | — | (63) | (25) | (86) | (60.1%) | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | — | — | (176.26) | (3.13) | (3.44) | (98.2%) | ||||||
| Cash flow | — | — | — | — | — | — | — | — | (148.19) | (4.38) | (2.73) | (97.0%) | ||||||
| Capex | — | — | — | — | — | — | — | — | (2.15) | (0.01) | (0.01) | (99.7%) | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (150.34) | (4.38) | (2.75) | (97.1%) | ||||||
| Book value | — | — | — | — | — | — | — | — | 55.04 | 37.45 | 11.03 | (32.0%) | ||||||
| Shares, m | — | — | — | — | — | — | — | — | 0 | 8 | 18 | +2,147.2% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | (53) | (35) | (82) | (33.6%) | |||||
| Capex | — | — | — | — | — | — | — | — | (1) | 0 | 0 | (93.2%) | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (54) | (35) | (83) | (34.5%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | 21 | 301 | 332 | +1,349.2% | |||||
| Net debt | — | — | — | — | — | — | — | — | (28) | (295) | (328) | +954.4% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | 20 | 301 | 332 | +1,429.1% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | 0.00 | (14.55) | (47.38) | (14.5) pt | |||||
| ROIC | — | — | — | — | — | — | — | — | 0.00 | (311.67) | (1,304.79) | (311.7) pt | ||||||
| ROE | — | — | — | — | — | — | — | — | 0.00 | (24.38) | (72.07) | (24.4) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 16 | 27 | — | +68.8% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 25 Oct 2026
LB Pharmaceuticals Inc vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| GHRS GH Research PLC | $1.3B | — (loss-making) | — | — | n/m | −66.62% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| URGN Urogen Pharma | $1.3B | — (loss-making) | — (loss-making) | +223.85% (above 0%: growing) | n/m | +63.95% (above 0%: growing) | 91.57% | 9.36% | Compare |
| OMER Omeros Corporation | $1.2B | 9.8× | 2.1× | +35.46% (above 0%: growing) | n/m | +118.70% (above 0%: growing) | 97.20% | 0.26% | Compare |
| LBRX LB Pharmaceuticals Inc | $1.2B | — (loss-making) | — | — | n/m | −579.03% (below 0%: shrinking) | — | 0.00% | |
| DRTS Alpha Tau Medical Ltd. | $1.2B | — (loss-making) | — | — | n/m | −30.42% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| NKTR Nektar Therapeutics | $1.2B | — (loss-making) | — (loss-making) | −9.34% (below 0%: shrinking) | n/m | −65.73% (below 0%: shrinking) | 100.00% | (417.94%) | Compare |
| SLN Silence Therapeutics PLC Sponsored ADR | $1.2B | — (loss-making) | — (loss-making) | +197.18% (above 0%: growing) | n/m | +106.95% (above 0%: growing) | 97.39% | 0.00% | Compare |
| MNKD MannKind Corporation | $1.2B | — (loss-making) | — (loss-making) | +24.04% (above 0%: growing) | n/m | −267.69% (below 0%: shrinking) | 0.00% | (2.14%) | Compare |
| AVLN Avalyn Pharma Inc. | $1.2B | — (loss-making) | — | — | n/m | — | — | 0.00% | Compare |
| Median of peers | $1.2B | — | — | +35.46% | — | −30.42% | 91.57% | 0.00% |
Pay and ownership Proxy statement filed 23 April 2026
Ownership
Directors and executive officers, together
5.80%
Entities affiliated with Deep Track Capital, LP
11.70%
RA Capital Healthcare Fund, L.P.
7.70%
Commodore Capital Master LP
6.80%
TCG Crossover Fund II, L.P.
6.40%
Trails Edge Biotechnology Master Fund, LP
6.00%
JPMorgan Chase & Co.
5.60%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement